Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EKF Diagnostics Launches New EKF Molecular Division

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
EKF Molecular to offer diagnostic technologies for cancer gene detection.

EKF Diagnostics has announced the launch of a new division to focus on molecular and companion diagnostics. EKF Molecular Diagnostics will develop technologies for cancer gene detection through its acquisition of UK based 360 Genomics.

EKF Molecular has been set up to offer innovative products with the potential to change current DNA extraction and detection practices, allowing EKF to address the fast growing companion diagnostics market.

Companion diagnostics are used to distinguish between which patients are most likely to benefit from a particular therapy or those patients where the therapy will prove ineffective or even harmful.

EKF Molecular’s lead product, PointMan™, is a real-time PCR technology that provides highly sensitive detection for cancer mutations.

PointMan is highly efficient in amplifying the target sequence of interest whilst suppressing amplification of the wild type.

The resulting sample is effectively enriched for the mutation thereby having the potential to offer industry leading sensitivity in a wide variety of sample types.

EKF Molecular expects to follow the spring launch of PointMan with several additional product launches during the second half of the year.

Xtract™ is the second product in EKF’s launch range. Xtract offers customers in the pharmaceutical, academic and diagnostic sectors a quicker, less expensive, cleaner and automatable platform for DNA extraction technology.
 
Julian Baines, Chief Executive Officer of EKF, said: “Companion diagnostics, is a situation where everyone wins: patients get better diagnosis which leads to better treatments and survival rates; doctors see increased patient safety and can make better informed decisions about treatments; healthcare providers and insurance companies will see better patient outcomes through reduced costs and pharmaceutical companies will be able to gain easier regulatory approval and a quicker time to market for their drugs.”

Andrew Webb has joined as Chief Executive Officer of EKF Molecular in a non-Board appointment.

Andrew joins from QIAGEN where he established and led global market development for the high growth personalized healthcare business, launching industry leading products.

Previously, Andrew was an executive director at DxS, the pioneering personalized healthcare company.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PointMan™ Enriches Low-level DNA Mutations from Whole Blood
Ultra-sensitive PointMan™ enables blood sampling instead of tissue biopsies for cancer patient mutation status assessment.
Wednesday, January 22, 2014
Scientific News
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Switch Lets Salmonella Fight, Evade Immune System
Researchers at the University of Illinois at Chicago have discovered a molecular regulator that allows salmonella bacteria to switch from actively causing disease to lurking in a chronic but asymptomatic state called a biofilm.
Genetic Cause of Rare Allergy
Institute has identified a genetic mutation responsible for a rare form of inherited hives induced by vibratory urticaria.
Mitochondria Shown to Trigger Cell Ageing
An international team of scientists has for the first time shown that mitochondria, the batteries of the cells, are essential for ageing.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Validating the Accuracy of CRISPR-Cas9
IBS Researchers create multiplex Digenome-seq to find errors in CRISPR-Cas9 processes.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!